Fax: (713) 792-2031
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure
Article first published online: 6 MAR 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 8, pages 1556–1560, 15 April 2007
How to Cite
Kantarjian, H., O'Brien, S., Talpaz, M., Borthakur, G., Ravandi, F., Faderl, S., Verstovsek, S., Rios, M. B., Shan, J., Giles, F. and Cortes, J. (2007), Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer, 109: 1556–1560. doi: 10.1002/cncr.22569
- Issue published online: 4 APR 2007
- Article first published online: 6 MAR 2007
- Manuscript Accepted: 3 JAN 2007
- Manuscript Revised: 21 DEC 2006
- Manuscript Received: 31 OCT 2006
- imatinib mesylate failure;
- chronic myelogenous leukemia;
The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented.
The outcome of 420 patients with CML post-imatinib failure (resistance-recurrence in 374; toxicities in 46) were reviewed in relation to survival, overall, and by different therapies.
The estimated 3-year survival rates were 72% in 88 patients who progressed in chronic phase, 30% in 130 patients who progressed in accelerated phase, 7% in 156 patients who progressed in blastic phase, and 75% in 37 patients in chronic phase with imatinib intolerance. Survival in chronic phase was better when subsequent therapy was nilotinib or dasatinib vs allogeneic stem cell transplant vs others (estimated 2-year survival rates 100% vs 72% vs 67%; P = .01), but not in accelerated-blastic phase.
Prognosis post-imatinib failure in chronic phase is reasonable; it is poor if the CML phase post-imatinib failure is accelerated or blastic. Cancer 2007. © 2007 American Cancer Society.